Başaran, G. ., Twelves, C. ., , Cortés, J. ., & Awada, A. . (2017). Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 63, 144-155. https://doi.org/10.1016/j.ctrv.2017.12.002 (Original work published 2017)

Schneeweiss, A. ., Park-Simon, T. ., Albanell, J. ., Lassen, U. ., Cortés, J. ., , … Cervantes, A. . (2018). Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investigational New Drugs. https://doi.org/10.1007/s10637-018-0562-4 (Original work published 2018)

Traina, T. ., Miller, K. ., Yardley, D. ., Eakle, J. ., Schwartzberg, L. ., O’Shaughnessy, J. ., … Cortés, J. . (2018). Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2016713495. https://doi.org/10.1200/JCO.2016.71.3495 (Original work published 2018)

Cortés, J. ., Podoltsev, N. ., Kantarjian, H. ., Borthakur, G. ., Zeidan, A. ., Stahl, M. ., … Uy, G. . (2021). Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. International Journal of Hematology, 113(1), 92-99. https://doi.org/10.1007/s12185-020-02994-8